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Lipid dropletsNeutral lipid storage diseasewithmyopathy (NLSD-M) is a rare autosomal recessive disorder characterised by an
abnormal accumulation of triacylglycerol into cytoplasmic lipid droplets (LDs). NLSD-M patients are mainly af-
fected by progressive myopathy, cardiomyopathy and hepatomegaly. Mutations in the PNPLA2 gene cause vari-
able phenotypes ofNLSD-M. PNPLA2 codes for adipose triglyceride lipase (ATGL), an enzyme that hydrolyses fatty
acids from triacylglycerol. This report outlines the clinical and genetic findings in a NLSD-M Italian family with
three affected members. In our patients, we identified two novel PNPLA2 missense mutations (p.L56R and
p.I193F). Functional data analysis demonstrated that these mutations caused the production of ATGL proteins
able to bind to LDs, but with decreased lipase activity. The oldest brother, at the age of 38, had weakness and at-
rophy of the right upper arm and kyphosis. Now he is 61 years old and is unable to raise arms in the horizontal
position. The second brother, from the age of 44, had exercise intolerance, cramps and pain in lower limbs. He is
currently 50 years old and has an asymmetric distal amyotrophy. One of the two sisters, 58 years old, presents the
same PNPLA2 mutations, but she is still oligo-symptomatic on neuromuscular examination with slight triceps
muscle involvement. She suffered from diabetes and liver steatosis. This NLSD-M family shows a wide range of
intra-familial phenotypic variability in subjects carrying the same mutations, both in terms of target-organs
and in terms of rate of disease progression.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
NLSD-M (MIM 610717) and NLSD-I (neutral lipid storage disease
with ichthyosis, MIM275630) are due tomutations in adipose triglycer-
ide lipase (ATGL) or in α/β-hydrolase domain-containing protein 5
(ABHD5) and are characterised by systemic triacylglycerol deposition
in cytoplasmic lipid droplets (LDs) in most tissues, including skeletal
and cardiac muscles, liver and peripheral blood [1]. LDs are virtually
present in all cell types, representing a reservoir of bioactive lipids and
lipid-derived hormones in adipose and non-adipose tissues [2]. The
white blood cell diagnostic feature of NLSD is characterised by lipid-
containing vacuoles in leukocytes, which was originally described by
Jordans [3,4]. Clinically, the main difference between NLSD-I and
NLSD-M is that a lack of ABHD5 results in early ichthyosis and oftenemistry and Molecular Biology,
arroti 30, 20145 Milan, Italy.
rk and should be considered as
. This is an open access article underliver involvement whereas a lack of ATGL essentially causes the pre-
dominant clinical phenotype with skeletal and cardiac myopathy [1].
In particular, NLSD-M patients are characterised by progressive my-
opathy (100%), cardiomyopathy (44%), elevated serum creatine kinase
(100%), hepatomegaly (20%), diabetes (24%), chronic pancreatitis
(14%) and short stature (15%) [5–11]. No ichthyosis is observed in pa-
tients suffering from NLSD-M, even though the skin of few patients ap-
pears to be particularly dry [12].
The onset of NLSD-M is caused bymutations in the PNPLA2 gene,which
codes for ATGL, a member of the patatin-like phospholipase domain-
containing proteins [5]. This lipase is a lipid droplet-associated protein
and catalyses the first step in the hydrolysis of triacylglycerols (TGs),
storedwithin LDs [1] therebygeneratingdiacylglycerols and free fatty acids.
The human ATGL protein consists of 504 amino acids divided into a
N-terminal part containing the patatin domain (amino acids 10 to 178)
with catalytic residues S47 and D166 and a C-terminal part containing a
hydrophobic lipid binding domain at position 315–360. ATGL's enzy-
matic activity is co-activated by ABHD5, a 39 kDa protein that associates
with LDs, and inhibited by the protein G0G1 switch gene 2 (G0S2). Thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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regulatory interactions with its co-activator ABHD5 and its inhibitor
G0S2 [13].
To the best of our knowledge, 41 NLSD-M patients have been clini-
cally and genetically characterised [5,14–21]. Twenty-seven different
PNPLA2 mutations, which could differently affect protein function or
production, have been described. Here, we report the clinical and genet-
ic findings of a NLSD-M family of Italian origin with three affected sib-
lings. Moreover, in order to highlight the effect that different gene
mutationsmay have on ATGL lipase activity, we have performed a func-
tional characterisation of the novel PNPLA2missense mutations identi-
fied in our patients.
2. Materials and methods
2.1. Muscle histopathology
Histopathological evaluation of muscle was performed according to
the standard procedures described by Dubowitz [22]. Light microscopy
of frozen cross sections of muscle biopsies was used for conventional
histochemical and histoenzymatic stains, including haematoxylin &
eosin (H&E), Gomori trichrome, Oil-Red-O (ORO), NADH-TR, COX,
SDH, acid phosphatase, acid and alkaline ATPases.
2.2. Cell culture
Fresh EDTA-treated peripheral blood samples (3 mL) from patients
were centrifuged at 3300 g for 10min. Buffy coatswere carefully collect-
ed by gentle pipette suction, immediately smeared onto slide glasses,
completely dried, and fixed with Biofix (Bio-Optica, Milan, Italy). May-
Grünwald–Giemsa (MGG) staining was carried out according to the
standard procedures. Human skin fibroblasts from patients were ob-
tained from skin biopsies and cultured in Earle's minimum essential
media (MEM)with 10% foetal bovine serum (FBS), 100 IU/mL penicillin
and 100mg/mL streptomycin at 37 °C in a 5% CO2 incubator. Fibroblasts
were observed under phase-contrast light microscopy and
photographed (40×; I X51, Olympus).
Fibroblasts (200,000 per dish) were also seeded on coverslips in
Earle's MEM culture medium and allowed to adhere for 36 h. Themedi-
um was then removed and cells were washed with Dulbecco's
phosphate-buffered saline (D-PBS), stained with Nile Red dye (NR, 9-
diethylamino-5Hbenzo[alpha]phenoxazine-5-one) and examined with
a LeicaMB5000Bmicroscope equippedwith 20×, 40× and 100× oil im-
mersion objectives. Fluorescence images were captured using a Leica
DFC480 R2 digital camera and a Leica Application Suite (LAS) software.
2.3. Molecular analysis
GenomicDNAwas extracted fromperipheral blood using a Puregene
DNA Isolation kit (Qiagen, Venlo, Netherlands). Primer sequences and
PCR amplification conditions for the analysis of PNPLA2 coding regions
(GenBank NM02376) were previously reported [5]. All PCR products
were purified (NucleoSpin Extract II, Macherey-Nagel, Germany) and
sequenced on 3730 DNA analyser by the BigDyew Terminator V1.1
Cycle sequencing kit (Applied Biosystems, Foster City, CA, USA).
Informed consent for genetic and histological analysis was obtained
from participants of the study. Moreover, written informed consent
from the patients was obtained for publication of the article and any ac-
companying images.
2.4. Generation of site-directed mutagenesis PNPLA2 plasmids and expres-
sion of recombinant mutants in HeLa cells
PNPLA2 cDNA has been previously cloned into pEGFP-N1 from
Clontech (Mountain View, CA, USA) to produce pEGFPN1-PNPLA2, ex-
pressing ATGL with GFP at the C-terminus. Point mutations wereperformed using the Phusion Site-Directed Mutagenesis Kit (Thermo
Scientific, Waltham, MA, USA). Mutations in pEGFP-PNPLA2 plasmid
were introduced using the following primers: S47A: forward 5′-CACA
TCTACGGCGCCGCGGCCGGGGCGCTCACGG-3′ and reverse: 5′-CCGTGA
GCGCCCCGGCCGCGGCGCCGTAGATGTG-3′; L56R: forward 5′-GCCACG
GCGCGGGTCACCGGGG-3′ and reverse 5′-CCCCGGTGACCCGCGCCGTG
GC; I193F: forward 5′-CGGGCGAGAGTGACTTCTGTCCGCAGGAC and re-
verse 5′-GTCCTGCGGACAGAAGTCACTCTCGCCCG. All constructs were
verified by DNA sequencing.
HeLa cells were cultured on glass coverslips in Dulbecco's modified
Eagle's medium with 10% FBS. 400 μM oleate complexed to BSA (6:1
molar ratio) was added to the medium and incubated overnight. The
cells were then transiently transfected with control and recombinant
PNPLA2 plasmids using the Lipofectamine 2000 transfection reagent, ac-
cording to the manufacturer's protocol (Life Technologies, Carlsbad, CA,
USA). After 24 h, the cells were fixed and stained with ORO, and LDs
from immunofluorescent images were examined with a Leica
MB5000B microscope. Fluorescence images were captured using a
Leica DFC480 R2 digital camera and a LAS software. Moreover, fluores-
cence images were also captured using a confocal microscope Leica
TCS SPE equipped with 63× oil immersion objective.
2.5. Triglyceride quantification in NLSD-M fibroblasts and HeLa transfected
cells
NLSD-M and control fibroblasts at the same passage (P8) were seed-
ed onto plates at a density of 1 × 106 cells/plate and cultured as previ-
ously described. The day after, the cells were homogenised in 1 mL
solution containing 5% TRITON X-100 (Sigma-Aldrich, Saint Louis, MO,
USA), incubated at 80 °C for 5min and centrifuged for 2min. Cellular tri-
glyceride content was quantified using Triglyceride Quantification Col-
orimetric Kit (Biovision, Milpitas, CA, USA), according to the
instructions. The absorbance was measured at 570 nm with EnVision
Multilabel Reader (PerkinElmer, Waltham, MA, USA).
5 × 105 HeLa transfected cells were cultured in DMEMwith 10% FBS
and supplemented with 400 μM oleate/BSA, and allowed to adhere
overnight. The day after, the cells were transiently transfected, as ex-
plained in paragraph 2.4. After 24 h, the cells were homogenised and
cellular triglyceride content was quantified using Triglyceride Quantifi-
cation Colorimetric Kit. Intracellular TG content was expressed as
nanomoles of TG per milligrammes of cellular protein.
2.6. Statistical and bio-informatic analysis
The statistical analysis of quantitative data on LDs identified from
cells (fibroblasts andHeLa transfected cells) by image analysis of immu-
nofluorescence experiments was made using SPSS v.19 package (SPSS,
Chicago, IL, USA). The values were compared using x2-squared test. A
P-value of ≤0.05 was considered to be statistically significant.
The effect of amino acid substitutions on protein function was pre-
dicted using ClustalW, SIFT and PolyPhen software. Amultiple sequence
alignment of mammalian ATGL proteinswas used as input for ClustalW.
The NCBI reference sequence (NP_065109.1) of the human ATGL pro-




Family's pedigree is showed in Fig. 1A.
3.1.1. Patient 1
The oldest brother is now 61 years old (Fig. 1B). Heworked as a clerk
for the rail network, although from the age of 40 he complained of be-
coming easily fatigued. From the age of 38, he had weakness and
Fig. 1. Clinical phenotype of NLSD-M patients. (A) Pedigree of the NLSD-M family; (B) patient II-1; (C) patient II-3.
Fig. 2.Muscle histopathology of two biopsies from patient II-1 (first biopsy, A,B,C; second biopsy D, E, F) and one biopsy from patient II-3 (G, H, I), stained with haematoxylin–eosin (A, D,
G), Gomori trichrome (B), NADH-TR reductase (E, H) and Oil-Red-O (C, F, I).
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underwent surgery for an abdominal teratoma. At the age of 50 years,
he experienced painful cramps in the arms especially after exercise.
Moreover, he complained of pain and rigidity to his right leg. He pre-
sented upper limb weakness at the age of 60 and he is now unable to
raise arms in the horizontal position (15 °C) and presents severe weak-
ness in his upper limbs with diffuse atrophy, more marked in right del-
toid, biceps and triceps muscles (Fig. 1B). Spirometry showed a
restrictive ventilatory insufficiency (forced vital capacity = 57%). Plas-
ma creatine kinase (CK) values varied between 804 and 1118 IU/L (nor-
mal values: 0–180 IU/L). Muscle biopsy from the deltoid was performed
at the age of 39; it showed lipid droplet accumulation positive with Oil-
Red-O staining (Fig. 2C, patient II-1), suggesting a lipid storage myopa-
thy. Moreover, vacuolated fibres were detected using H&E and Gomori
trichrome staining (Fig. 2A and B). At the age of 40, he underwent a
biopsy of the quadriceps; Oil-Red-O staining revealed a lipid abnor-
mal storage, Gomori trichrome staining evidenced a lower degree
of fibre vacuolisation, and NADH-TR stain showed some atrophic
fibres and irregular staining (Fig. 2E and F). The patient had normal
plasma and urine carnitine levels, but a low total plasma carnitine
(27.9 nanomoles/mL; normal 36.2–72.9 nanomoles/mL). Liver function
tests revealed mildly elevated values of aspartate aminotransferase
(AST = 79U/L, normal range 4–40) and alanine aminotransferase
(ALT = 72 U/L, normal range 4–40), while normal values of gamma
glutamyl transpeptidase (GGT), serum albumin and bilirubin were
found. A mild hypercholesterolemia was noted (222 mg/dL, normal
range b200). EMG was myopathic.
At the age of 59, an abdominal ultrasound showed a mild hepatic
steatosis with liver enlargement. ECG and cardiac ultrasound were
normal.
3.1.2. Patient 2
This is the 50 year-old brother of patient II-1.
From the age of 35, he had exercise intolerance, cramps and pain in
lower limbs, especially in the right calf, and had scoliosis and scapular
winging (Fig. 1C). A muscle biopsy was taken from the quadriceps at
the age of 37. Vacuoles were detected using H&E and Oil-Red-O stain
and atrophic type I fibres reactive using NADH-TR stain (Fig. 2G, H and
I). In the same period he developed a progressive weakness of the
right arm. He currently has an asymmetric distal amyotrophy. His plas-
ma CK level was 1389 U/L, while serum hypertriglycerides (176 mg/dL,
normal range b175) and cholesterolemia (208 mg/dL, normal range
b200)were in upper limits. Liver function tests revealed slightly elevat-
ed values of aspartate aminotransferase (AST=45U/L, normal range 4–
40) and alanine aminotransferase (ALT = 57 U/L, normal range 4–40).
3.1.3. Patient 3
Patient 3 is the sister of the two above brothers. She is presently
58 years old.
For many years, she suffered from diabetesmellitus and required in-
sulin therapy. The last examination revealed blood glucose levels of
305 mg/dL (normal range 70–110) and plasma parameters for ALT,
AST, and GGT were elevated indicating impaired liver function. Choles-
terol and triglycerides were also elevated (298 mg/dL and 274 mg/dL,
respectively). An abdominal ultrasound showed a hyperechogenic liver,
for which she underwent a liver biopsy that revealed hepatic steatosis.
Her CK value was 724 U/L. Currently, she has mild weakness in her
right triceps brachiimuscle, but in othermuscles she has normal strength.
All three siblings showed Jordans' anomaly (Fig. 3A) in leukocytes
and abnormal lipid storage into LDs in skin fibroblasts (Fig. 3B and C).
The intracellular TG content from patients and control fibroblasts
has been determined in order to show the degree of LD accumulation.
As expected, the TG content in fibroblasts from patients was significant-
ly higher than in control fibroblasts (P b 0.001) (Supplementary Fig. 1).
There was also a significant difference in the TG amount between the
oldest patient II-1 and the other two (patient II-2 and patient II-3;P b 0.001; P b 0.05), while no significant difference was detected be-
tween patient II-2 and patient II-3 (P = 0.417).
3.2. Genetic analysis
Sequencing of the PNPLA2 gene confirmed the suspected clinical di-
agnosis of NLSD-M. Our patients were compound heterozygotes for two
novel missense mutations, c.177TNG (p.L56R) and c.577ANT (p.I193F)
(Fig. 4A and B). These mutations were not observed in 200 alleles
from control subjects, and they were submitted to GenBank (accession
numbers: KF833264 and KF833265). The first mutation (p.L56R) is
localised in the catalytic site, very near to serine 47, which is part of
the catalytic dyad of ATGL (Fig. 4C and D). The second variation
(p.I193F) is localised in a region close to the patatin domain (Fig. 4C
andD). Amultiple sequence alignment ofmammalian ATGL proteins re-
vealed complete conservation of leucine 56 and isoleucine 193 (Fig. 2S).
Moreover, according to bio-informatic prediction tools (SIFT and
PolyPhen-2), the p.L56R and the p.I193Fmutations are to be considered
as “damaging” (Fig. 2S).
3.3. Functional study of missense PNPLA2 mutations
To verify the pathogenic effect of the PNPLA2 allelic mutations iden-
tified in our patients, we constructed different recombinant plasmids
expressing ATGL fused to a GFP tag. The plasmids contained either
human PNPLA2 cDNA (pPNPLA2-EGFP), human PNPLA2 with the
p.L56R mutation (pPNPLA2-L56R-EGFP) and human PNPLA2 with the
p.I193Fmutation (pPNPLA2-I193F-EGFP). For comparison,we have pre-
viously constructed human PNPLA2 with p.S47A mutation. S47 amino-
acid is located in the core of catalytic domain and is essential for enzyme
activity. We observed in HeLa cells transfected with both wild type
pPNPLA2-GFP or mutated PNPLA2 plasmids, that all ATGL proteins
were able to bind to LDs (Fig. 5A). Furthermore the correct localization
of ATGL mutant proteins on LD surface has been clearly highlighted by
confocal microscopy images (Fig. 5B). While transfection with the pos-
itive control (pPNPLA2-EGFP) strongly reduced the number and area of
the LDs, transfection of the mutant plasmids pPNPLA2-L56R-EGFP and
pPNPLA2-I193F-EGFP has a significant minor effect (P b 0.001) (Fig. 5,
graphs C and E). The PNPLA2 mutations identified in our patients
(p.L56R and p.I193F) maintain a residual enzymatic activity (L56R:
number of LDs per cells 29%, area of LD sections 27%; I193F: number
of LDs per cells 39%, area of LD sections 38%) if compared to pPNPLA2-
S47A-EGFP, considered as totally inactive. The level of activity of
ATGL(S47A) is significantly lower in comparison with those of the
L56R and I193F mutant proteins (P b 0.001) (Fig. 5, graphs D and F).
In agreement with data obtained from quantitative analysis of im-
munofluorescence images (Fig. 5C and E), the intracellular TG content
in HeLa cells overexpressing GFP taggedmutants andwt ATGL confirms
that ATGL(L56R) and ATGL(I193F) proteins present a residual lipase ac-
tivity (Fig. 5G). Furthermore, a slight difference between the twomuta-
tions identified in our family is evidenced. The ATGL(L56R) seems to be
mostly impairedwith respect to ATGL(I193F) (Fig. 5C, E andG). The sta-
tistical analysis that compares data from graphs C, E and G has been re-
ported (Fig. 5D, F and H). The number of LDs per cell in ATGL(I193F)
mutant is significantly lower than ATGL(L56R) (P b 0.05) (Fig. 5D).
Concerning the data relative to the area of LD sections and the TG con-
tent, the difference between ATGL(I193F) and ATGL(L56R) has the
same trend, although not statistically significant (P = 0.292 and P =
0.262 respectively) (Fig. 5F and H).
4. Discussion
Until now, eight different PNPLA2 missense mutations have been
identified in NLSD-M patients. They represent almost 25% of gene vari-
ations and are mainly localised in the patatin domain of the protein, or
very close to it. With the exception of those described in this study,
Fig. 3. Histochemical characterization of NLSD-M patients. (A) Microphotographs of Jordans' bodies in patient's buffy coats stained with May-Grünwald Giemsa (100× magnification);
(B) culturedfibroblasts from affectedpatients (II-1, II-2 and II-3), phase contrast images (40×magnification); (C) culturedfibroblasts from affectedpatients (II-1, II-2 and II-3), fluorescent
microscopy images with Nile red staining (40× magnification).
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truncating mutation. Here, we have reported a NLSD-M Italian family
with three affected siblings, which are compound heterozygotes forFig. 4. Identification of PNPLA2mutations. (A,B) Electropherograms of PNPLA2 exon 2 and exon
tein. The patatin domain is located between amino acids I10 and L178 and contains the catalyt
(D) Schematic representation of ATGLmutant proteins. In the scheme, the localisation of the am
L178), while the p.I193F mutation is localised close to the same region.two novel PNPLA2 missense mutations. The p.L56R is located near the
residue S47 of ATGL catalytic dyad, while the second one, p.I193F, in a
highly conserved amino acid sequence near the patatin region. Our5 showing the c.167TNG and the c.577ANT mutations. (C) Structural domains of ATGL pro-
ic dyad (S47 and D166). The hydrophobic domain (P315–P360) is the LD-binding region.
ino acid substitutions is reported: the p.L56Rmutation falls into the patatin domain (I10–
Fig. 5. Transient transfection of ATGLmutant proteins in HeLa cells. (A) and (B) Qualitative evaluation of HeLa cells transiently transfectedwith the following plasmids: pEGFP empty vec-
tor (V), pPNPLA2-EGFP (WT), pPNPLA2(S47A)EFGP, pPNPLA2(L56R)EFGPand pPNPLA2(I193F)EFGP. LDs stainedwithORO are in red. Fluorescence of PNPLA2-EGFP recombinant proteins is
in green. Images have been captured with immunofluorescent microscope (A) and confocal microscope (B). The cells were analysed for number (C) and dimension (E) – cross section
area – of LD per cell. The values represent the means of almost 100 cells for each transfected mutant. (G) Quantification of TG content in HeLa cells transfected with pEGFP empty vector
(V), pPNPLA2-EGFP (WT), pPNPLA2(S47A)EFGP, pPNPLA2(L56R)EFGP and pPNPLA2(I193F)EFGP. The graph represents TG content from three independent experiments. In (D), (F) and
(H) are reported the statistical analysis of data concerning graphs C, E and G. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version
of this article.)
115S. Missaglia et al. / Molecular Genetics and Metabolism 115 (2015) 110–117results show that these mutations partially impair lipase function. Both
L56R and I193FATGL proteins are able to bind to cytoplasmic lipid drop-
let and to exert an enzymatic activity, albeit limited if compared with
wild type ATGL. The late-onset and slow progression of the myopathyobserved in our patients are in agreement with these molecular find-
ings. It must be noted that myocardial dysfunction was not observed
in the affected siblings, thus underlining that cardiac involvement
could be related to a different degree of biochemical defect [18]. All
116 S. Missaglia et al. / Molecular Genetics and Metabolism 115 (2015) 110–117patient-carrying missense mutations manifested a milder degree of se-
verity, with the exception of patient described by Coassin et al., inwhich
the p.D166G ATGL mutation directly disrupted catalytic dyad [5,9,10,
17–19]. Previous results and those reported in this study show that ge-
notype–phenotype correlation, regarding PNPLA2 missense mutations
and heart disease, should be carefully taken into account to ensure an
accurate NLSD-M patient's prognosis, especially when supported by
functional studies. Notably, compelling biochemical and molecular ap-
proaches, supported by statistical analysis, are highly recommended
reporting new cases of enzymes mutations in humans and their meta-
bolic consequences.
In our patients, histochemical inspection of tissues revealed an ab-
normal accumulation of lipids in muscle fibres, leukocytes and cultured
skin fibroblasts. The defect of lipolysis explains the systemic triglyceride
storage, distinctive from carnitine deficiency syndrome or other disor-
ders of fatty acid oxidation. The present disorder is accompanied by rel-
atively mild clinical symptoms as compared with carnitine deficiency,
while cramps can be also seen in carnitine-palmitoyl-transferase
deficiency [23].
In our family, we observed a spectrum of phenotypes, ranging from
relatively asymptomatic to full expression of a severe myopathy. This
was unexpected considering that the oldest patient and his sister are
now in their seventh decade of life (61 and 58 years, respectively).
Moreover, they present an asymmetric right-sidedmuscle involvement
of upper and lower limbs. Previous studies have highlighted the pre-
dominance of myopathy in the right side [24]. Intra-familiar clinical
phenotypic variability emphasises heterogeneity of muscle involve-
ment in spite of similar genetic background. In addition, an unusual
liver involvement in the absence of overt clinical muscle weakness,
was observed in the female patient. Hepatomegaly and liver steatosis
are frequently detected in NLSD-I patients (more than 80%) and are con-
sidered as early clinical symptoms together with ichthyosis. Instead, in
NLSD-M subjects, liver damage has been noted in only 20% of
cases [24], in association with skeletal and cardiac myopathy.
In conclusion, we have found a wide range of intra-familial pheno-
typic variability in patients carrying the same mutations, both in terms
of target-organs and severity of the disease. Currently, molecular
knowledge about the biochemical function of ATGL and ABHD5 is in-
complete and does not allow us to explain the differences in the clinical
manifestations observed in the subject family's members. The enzymat-
ic mechanisms of the lipolytic process and the patho-physiological im-
pact of lipolysis on energy homeostasis in different cell tissues are
complex and regulated by extra- or intracellular signalling molecules
[2,25]. We may hypothesise that genetic variants and functional poly-
morphisms of genes other than PNPLA2 or ABHD5 can be involved and
differently affect clinical manifestation. Moreover, other factors in addi-
tion to the genotypemay concur to the clinical expression of the disease,
such as diet, gender and life style. This rare progressive disorder needs a
global collaboration to identify therapeutic strategies and compare clin-
ical phenotypes; for this purpose the international registry for NLSD has
been established (www.tgcv.org/r/home.html). In some NLSD-M fami-
lies with two affected siblings, clinical intra-familial heterogeneity has
already been reported. In the subject family, three out of four siblings
were affected and showed outstanding differences both in age of
onset and clinical symptoms. This study contributes further to the de-
scription of the genetic and to widen the clinical spectrum associated
with NLSD-M.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgme.2015.05.001.
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